<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04309773</url>
  </required_header>
  <id_info>
    <org_study_id>APHP180668</org_study_id>
    <nct_id>NCT04309773</nct_id>
  </id_info>
  <brief_title>Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy</brief_title>
  <acronym>BEZASCLER</acronym>
  <official_title>Double Blind, Multicentric, Randomized, Placebo-controlled Trial, Evaluating the Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the effect of bezafibrate treatment compared to&#xD;
      placebo on efficacy and safety in patients with primary sclerosing cholangitis (PSC) and&#xD;
      persistent cholestasis despite ursodeoxycholic acid therapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, randomized, double-blind, placebo-controlled, evaluation of the efficacy&#xD;
      and safety of Bezafibrate in subjects with PSC and persistent cholestasis despite&#xD;
      ursodeoxycholic acid therapy (UADC).&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  A multicentre, double-blind placebo controlled, randomised clinical trial&#xD;
&#xD;
        -  35 centers participants to the recruitment (French Network of Reference and Competence&#xD;
           Centers for Rare Diseases: &quot;inflammatory biliary diseases and autoimmune hepatitis&quot;&#xD;
           (MIVBH), including Saint-Antoine hospital, Paris as reference coordinator center)&#xD;
&#xD;
      Sample size :&#xD;
&#xD;
      104 patients, 52 in each group&#xD;
&#xD;
      Treatments groups:&#xD;
&#xD;
        1. UADC therapy (15-20 mg/kg/d) + Bezafibrate (400mg/d)&#xD;
&#xD;
        2. UDCA therapy (15-20 mg/kg/d) + placebo of bezafibrate (400mg/d)&#xD;
&#xD;
      Treatments duration :&#xD;
&#xD;
      24 months&#xD;
&#xD;
      Assessement:&#xD;
&#xD;
      Study visits at Inclusion, (M0) Randomisation and then every 3 months until M24&#xD;
&#xD;
      This is a phase III randomized, double blinded, multicenter, study.&#xD;
&#xD;
      No interim analysis is planned. Analysis will be performed at the end of the study after data&#xD;
      review and freezing of data base according to intent to treat principle.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the efficacy of 24-month treatment with bezafibrate (400 mg/day) versus placebo in addition to standard UDCA therapy in Primary Sclerosing Cholangitis (PSC).</measure>
    <time_frame>At 24 months</time_frame>
    <description>Proportion of patients with serum Alkaline Phosphatase &lt; 1.5 ULN and a reduction of at least 15% from baseline at M24 and normal serum bilirubin and no increase of liver stiffness at M24 compared to baseline:</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with clinical or biological adverse events</measure>
    <time_frame>At 24 months</time_frame>
    <description>Safety endpoint: Percentage of patients with clinical (including increased IBD activity) or biological adverse events (elevated creatinine (&gt; 150 μmol/L) or ALT (&gt; 5ULN) or AST (&gt; 5ULN) or CPK (&gt; 5ULN) during the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of PSC patients</measure>
    <time_frame>At 12 months and 24 months</time_frame>
    <description>French version of the quality of life QMCF questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score for pruritus</measure>
    <time_frame>At 12 months and 24 months</time_frame>
    <description>Absolute changes in the score for pruritus (measured by VAS and 5D pruritus scale) at each study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue score</measure>
    <time_frame>At 12 months and 24 months</time_frame>
    <description>Absolute changes in the score for fatigue (measured by adapted PBC-40 questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of liver biochemical parameters between the two groups of patient</measure>
    <time_frame>between month 0 and month 24</time_frame>
    <description>The course during the study will be studied using linear regression mixed model.&#xD;
A random effect for each patient will be considered and treatment group will be considered as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of clinical events and transplant-free survival</measure>
    <time_frame>At 24 months</time_frame>
    <description>Survival rate without liver transplantation or hepatic events (ascites, variceal bleeding, encephalopathy, acute cholangitis, cholangiocarcinoma, hepatocellular carcinoma or serum total bilirubin &gt; 100 μmol/L for at least 3 months).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Primary Sclerosing Cholangitis</condition>
  <condition>Cholestasis</condition>
  <arm_group>
    <arm_group_label>Bezafibrate in addition to standard UDCA therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bezafibrate (400mg) in addition to standard 15-20 mg/kg/day UDCA therapy (&quot;experimental&quot; arm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo of Bezafibrate in addition to standard UDCA therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of Bezafibrate in addition to standard 15-20 mg/kg/day UDCA therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy</intervention_name>
    <description>Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy Treatment duration : 24 months Bezafibrate/AUDC : daily oral dose</description>
    <arm_group_label>Bezafibrate in addition to standard UDCA therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Bezafibrate in addition to standard UDCA therapy</intervention_name>
    <description>Placebo of Bezafibrate (400mg) in addition to standard 15-20 mg/kg/Day UDCA therapy Treatment duration : 24 months Placebo/AUDC : daily oral dose</description>
    <arm_group_label>Placebo of Bezafibrate in addition to standard UDCA therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females ≥ 18 and ≤ 75 years&#xD;
&#xD;
          -  Large duct PSC verified by retrograde, operative, percutaneous or magnetic resonance&#xD;
             cholangiography (MRC) demonstrating intrahepatic and /or extrahepatic biliary duct&#xD;
             changes consistent with PSC&#xD;
&#xD;
          -  Colonoscopy within the last 5 years (or within 3 months if IBD is associated to PSC)&#xD;
             with no cancer nor all-grade dysplasia&#xD;
&#xD;
          -  ALP ≥ 1.5 ULN at baseline&#xD;
&#xD;
          -  Treatment with UDCA (15-20 mg/kg/d) for ≥ 6 months before inclusion.&#xD;
&#xD;
          -  Using contraceptive in childbearing women&#xD;
&#xD;
          -  Affiliation to a social security system (AME excepted)&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Child-Pugh score B or C&#xD;
&#xD;
          -  Ascites or digestive hemorrhage (or history of)&#xD;
&#xD;
          -  Total bilirubin in the last 3 months &gt; 50 μmole/L (3 mg/dl)&#xD;
&#xD;
          -  Gilbert syndrome defined as unconjugated bilirubinemia &gt; 12 μmol/L&#xD;
&#xD;
          -  Albumin in the last 3 months &lt; 35 g/L&#xD;
&#xD;
          -  Prothrombin index in the last 3 months &lt; 70%&#xD;
&#xD;
          -  Platelets count in the last 3 months &lt; 100000/mm3&#xD;
&#xD;
          -  ALT or AST &gt; 5 ULN in the last 3 months&#xD;
&#xD;
          -  Prior liver transplantation&#xD;
&#xD;
          -  Treatment with a fibrate within the last 3 months inclusion or with a statin at&#xD;
             inclusion&#xD;
&#xD;
          -  Current active IBD defined as either current use of systemic corticosteroid therapy &gt;&#xD;
             10 mg/day or budesonide &gt; 3 mg /day or immunosuppressive drugs (cyclosporine,&#xD;
             tacrolimus, mycophenolate mofetil, mTor inhibitors) or biologics (vedolizumab,&#xD;
             ustekinumab) or a partial Mayo score &gt; 2 in patients with ulcerative colitis (UC) or a&#xD;
             Crohn's Disease Activity Index (CDAI) &gt; 150 in patients with Crohn's disease (CD)&#xD;
&#xD;
          -  Dose change of treatment for associated IBD ≤3 months prior to inclusion&#xD;
&#xD;
          -  Current or history of colonic cancer or all-grade dysplasia described at the last&#xD;
             colonoscopy&#xD;
&#xD;
          -  Any other cause of liver damage ((positive test for HBV, HCV, or HIV, excessive&#xD;
             alcohol consumption, hemochromatosis, Wilson's disease, α1-antitrypsin deficiency,&#xD;
             celiac disease, autoimmune hepatitis defined by the presence of at least 2 of the 3&#xD;
             following criteria; 1) AST or ALT &gt; 5 ULN, 2) Positive anti smooth muscle auto&#xD;
             antibodies or serum IgG &gt; 1.5 ULN, 3) interface hepatitis on liver biopsy)&#xD;
&#xD;
          -  Secondary causes of sclerosing cholangitis including IgG4-associated cholangitis&#xD;
             (elevated serum IgG4 &gt; 4 ULN)&#xD;
&#xD;
          -  History of acute cholangitis in the last 3 months prior to inclusion or current acute&#xD;
             cholangitis&#xD;
&#xD;
          -  Endoscopic treatment for bile duct stenosis ≤ 3 months prior to inclusion or planned&#xD;
             within 3 months post randomization date&#xD;
&#xD;
          -  History of or established or suspected hepatobiliary carcinoma.&#xD;
&#xD;
          -  Any severe comorbidity that may reduce life expectancy&#xD;
&#xD;
          -  History of malignancy diagnosed or treated within 2 years (recent localized treatment&#xD;
             of squamous or non-invasive basal skin cancers is permitted; cervical carcinoma in&#xD;
             situ is allowed if appropriately treated prior to Screening)&#xD;
&#xD;
          -  Known hypersensitivity to bezafibrate, any of the components of Befizal© or other&#xD;
             fibrates&#xD;
&#xD;
          -  Known photosensitivity or photoallergy reactions to fibrate&#xD;
&#xD;
          -  Patient with congenital galactosemia, glucose malabsorption, or lactase deficiency&#xD;
             because of presence of lactose in 400 mg SR tablets of bezafibrate and in placebo&#xD;
             tablets&#xD;
&#xD;
          -  Pregnancy (or desire for)&#xD;
&#xD;
          -  Renal insufficiency (clearance &lt; 60 ml/min or serum creatinine level &gt; 130 μmole/L)&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Participation in any other interventional study or in the exclusion period any other&#xD;
             interventional study&#xD;
&#xD;
        Randomization exclusion criteria:&#xD;
&#xD;
          -  Positive test for HBV (positive HBs Ag), HCV (positive HCV RNA), or HIV (positive&#xD;
             serology)&#xD;
&#xD;
          -  Pregnancy (or desire for in the 2 next years)&#xD;
&#xD;
          -  Secondary causes of sclerosing cholangitis including IgG4-associated cholangitis&#xD;
             (elevated serum IgG4 &gt; 4 ULN)&#xD;
&#xD;
          -  Autoimmune hepatitis defined by the presence of at least 2 of the 3 following&#xD;
             criteria; AST or ALT &gt; 5 ULN, Positive anti smooth muscle auto antibodies or serum IgG&#xD;
             &gt; 1.5 ULN, interface hepatitis on liver biopsy&#xD;
&#xD;
          -  Current acute cholangitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier CHAZOUILLERES, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier CHAZOUILLERES, professor</last_name>
    <phone>+ 33149282380</phone>
    <email>olivier.chazouilleres@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christophe CORPECHOT, docteur</last_name>
    <phone>00 33 1 49 28 28 36</phone>
    <email>christophe.corpechot@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hepatology department - Hopital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier CHAZOUILLERES, Pr</last_name>
      <phone>+ 33 (0) 1 49 28 23 80</phone>
      <email>olivier.chazouilleres@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Christophe Corpechot, Doctor</last_name>
      <phone>+ 33 (0) 1 49 28 28 36</phone>
      <email>christophe.corpechot@aphp.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 18, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2020</study_first_posted>
  <last_update_submitted>July 31, 2021</last_update_submitted>
  <last_update_submitted_qc>July 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary sclerosing cholangitis</keyword>
  <keyword>Persistent cholestasis</keyword>
  <keyword>Bezafibrates</keyword>
  <keyword>Fibrates</keyword>
  <keyword>UDCA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
    <mesh_term>Bezafibrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

